icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
" In view of :
- the efficacy and safety data versus placebo,
- the absence of direct comparative data versus other anti-ANF agents, particularly infliximab,
the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies."
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
TdYMK7GMBaEejHr4